Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$47.18 USD

47.18
571,622

-0.25 (-0.53%)

Updated Aug 8, 2025 10:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

by Zacks Equity Research

Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

    Arpita Dutt headshot

    Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

    by Arpita Dutt

    Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

      Zacks Equity Research

      Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

      by Zacks Equity Research

      Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

        Arpita Dutt headshot

        Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

        by Arpita Dutt

        Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

          Zacks Equity Research

          Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

          by Zacks Equity Research

          Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.

            Zacks Equity Research

            Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

            by Zacks Equity Research

            Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

              Zacks Equity Research

              Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised

              by Zacks Equity Research

              Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.

                Zacks Equity Research

                Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings?

                by Zacks Equity Research

                Investor focus should be on Eylea's performance and uptake of Dupixent when Regeneron Pharmaceuticals (REGN) reports third-quarter results

                  Zacks Equity Research

                  Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

                  by Zacks Equity Research

                  Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.

                    Zacks Equity Research

                    Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak

                    by Zacks Equity Research

                    Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.

                      Zacks Equity Research

                      BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

                      by Zacks Equity Research

                      BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

                        Zacks Equity Research

                        Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong

                        by Zacks Equity Research

                        Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers

                          by Arpita Dutt

                          It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.

                            Zacks Equity Research

                            Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls

                            by Zacks Equity Research

                            Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.

                              Zacks Equity Research

                              Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco

                              by Zacks Equity Research

                              Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

                                Zacks Equity Research

                                Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi

                                by Zacks Equity Research

                                Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi

                                  Arpita Dutt headshot

                                  Pricing Pressure, Competition Remain Headwinds for Pharma Stocks

                                  by Arpita Dutt

                                  Although the pharma and biotech sectors have rebounded in 2017, drug companies may find it a bit difficult to justify their high prices.

                                    Zacks Equity Research

                                    Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

                                    by Zacks Equity Research

                                    Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

                                      Zacks Equity Research

                                      Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up

                                      by Zacks Equity Research

                                      Flexion Therapeutics (FLXN) announced that its non-opioid intra-articular injection for treating knee pain has received FDA approval.

                                        Zacks Equity Research

                                        Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit

                                        by Zacks Equity Research

                                        Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal

                                          by Arpita Dutt

                                          The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.

                                            Zacks Equity Research

                                            Regeneron and Sanofi Get Favorable Ruling Against Amgen

                                            by Zacks Equity Research

                                            Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.

                                              Mark Vickery headshot

                                              Top Research Reports for HSBC, UPS & General Motors

                                              by Mark Vickery

                                              Today's Research Daily features new research reports on 16 major stocks, including HSBC (HSBC), United Parcel Service (UPS) and General Motors (GM)

                                                Zacks Equity Research

                                                Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat

                                                by Zacks Equity Research

                                                Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.

                                                  Zacks Equity Research

                                                  Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak

                                                  by Zacks Equity Research

                                                  Sanofi's (SNY) Genzyme and Vaccines units are driving sales. Sales from the Diabetes franchise however continue to drop.